super. ace BROOKINGS, S.D. (AP) — Mark Gronowski ran for two touchdowns and passed for two more and two-time defending national champion South Dakota State dominated Montana 35-18 in a second-round FCS playoff game on Saturday. While Gronowski was leading an offense that piled up 399 yards, the third-seeded Jackrabbits' defense held the 14th-seeded Grizzlies to 306 yards — but 160 came on two fourth-quarter touchdown drives after the lead reached 35-3. Adam Bock contributed a 30-yard interception return in the fourth quarter. South Dakota State (11-2), which beat Montana 23-3 in the national championship game in January, is home next weekend against sixth-seed Incarnate Word (11-2). Gronowski was 12-of-16 passing for 151 yards. He hit Griffin Wilde for a pair of touchdowns covering 34 and 24 yards in the second quarter and scored on a pair of 1-yard sneaks in the first and fourth. He also had a 21-yard reception to set up his first quarter run that put the Jackrabbits on top 7-3. Wilde had seven catches for 114 yards. Amar Johnson had 103 yards on 16 carries and Angel Johnson totaled 91 yards on 13 rushes. Keali'i Ah Yat was 19 of 32 for 231 yards but had two critical interceptions for Montana (9-5). In addition to the pick-6, Tucker Large had a goal-line interception when the Grizzlies could have pulled within four points. The Jackrabbits were 7 of 12 on third down, while the Grizzlies went 5 of 13 — 2 of 9 through three quarters. AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football . Sign up for the AP’s college football newsletter: https://apnews.com/cfbtop25

CLEMSON — Cade Klubnik threw for three touchdowns, backup running back Jay Haynes scored twice on the ground and defensive tackle Payton Page had a 57-yard pick-6 score as No. 17 Clemson routed The Citadel 51-14 Saturday to move to 39-0 all-time against FCS opponents. The Tigers (9-2) won their third straight and still held on to feint hopes of reaching the Atlantic Coast Conference title game and the College Football Playoff. Clemson, which finished ACC play at 7-1 with last week's 24-20 win at Pittsburgh, needs No. 11 Miami to lose at Syracuse next week to play for a league crown for the eighth time in 10 seasons. Clemson cranked it up early in this one, looking a lot like the offense that averaged better than 48 points during a six-game win streak earlier this season instead of the one that had not surpassed 24 points in any of its past three contests. Klubnik connected with Antonio Williams for a 30-yard TD to start the scoring and then the 315-pound Page stretched out for an interception and rumbled along the left sidelines — losing momentum with each step — for Clemson's first score from a defensive lineman in four years and a 14-0 lead. And Page wasn't the only defender to score. Clemson's All-American linebacker Barrett Carter playing his next-to-last home game, had a 4-yard TD run on Senior Day to end the Tigers' scoring. The Citadel (5-7), of the FCS Southern Conference, went on to its 19th straight loss to Clemson since 1932. Klubnik completed 12 of 16 passes for 198 yards. He headed to the sidelines after his second TD pass to Williams that gave the Tigers a 42-0 lead in the third quarter. Haynes got the bulk of the work after starter Phil Mafah achieved his 1,000-yard rushing season with three first-quarter runs. Haynes had scoring runs of 70 and 9 yards. The takeaway The Citadel: The Bulldogs are the leaders among FCS teams in victories over FBS opponents with nine since the college football split into Division I and Division I-AA in 1978. They couldn't stay competitive, but did roll up a season-high 288 yards rushing and scored a touchdown against Clemson for the first time in the past four games in the series. Clemson: The Tigers reached nine wins in a season for the 14th-straight time. Only Alabama, which entered the season with 16 straight nine-win seasons, had a longer current streak. Up next The Citadel's season is complete. Clemson closes the regular season with its rivalry game with South Carolina on Saturday.

One of the key features of "Keling AI" is its ability to generate personalized storytelling suggestions based on individual directorial styles and preferences. By leveraging the power of AI, filmmakers can now access a wealth of creative resources and ideas to enhance their storytelling capabilities and resonate with audiences on a deeper level.

Throughout the trial, both the prosecution and the defense presented compelling arguments. The prosecution painted the soldier as a violent aggressor who had used excessive force, while the defense argued that the soldier had acted in self-defense to protect himself from harm. The key piece of evidence was a surveillance video that captured the incident, but its interpretation was hotly contested by both sides.In what has become a bit of an annual tradition , I sat down with Amazon CTO Werner Vogels at AWS re:Invent this week . Another annual tradition now is that Vogels, who joined Amazon in 2004, publishes a series of predictions for the next year. It’d be easy to think that this year’s predictions are all about AI, but instead, Vogels focuses on how Millennials and Gen Z think about being part of the workforce, nuclear energy, combatting misinformation, open data for disaster preparedness, and the need for intention-driven technology. Unlike his employer, whose keynotes this week focused almost exclusively on AI, Vogels only mentions it three times in his written predictions “ for 2025 and beyond .” And while AI is now a steady drone in the background, he seems to be more preoccupied with how technology in general is shaping the world right now. The next generation of employees “I’ve been very much interested in looking at companies that are interested in solving really hard human problems, really big problems, like economic equality, whether it’s food, health care globally,” he told me. “And with that whole ‘Now Go Build’ documentary series, we’ve raised some of those. But one of the things that I’ve been noticing in the past, let’s say four or five years, is that there is a new generation of workers out there that are actually willing to take a pay cut if they can work for a company that has sustainability in mind — all these issues.” He also said that he has heard from a number of NGOs that there is a massive increase in tech workers who would like to volunteer at these organizations. “Where, in the past — five, ten years ago, you would have to beg for people to come. Now people knock on the door,” he said. “The problem that these companies have is how to manage them. They don’t actually have the people. An organization like Mercy Corps, for example, they only have two people that are in tech, right? Because that money goes to the area [where] they can actually have impact. They don’t go on the tech side....Now, they have an engineer for two weeks. They have all these great ideas that they want to do, and even companies that are coming to them saying: ‘Oh, you can have our products for free.’ But they do not have the people to work on this.” Vogels believes — and I think a lot of people would back him up — that the next generation of workers will also bring this mindset to the companies they work for, and that these companies will have to adapt to them. “That means as employers, if you’re interested in actually hiring the absolute best engineers, you better make sure that you change your company culture to actually be able to attract these people. It’s no longer: do I get the best laptop? Do I get the best screen? Do I get two screens, right? But does my work matter? And that’s a really big shift, because it’s no longer about what’s the salary I’m getting? Because I’m willing to give up some of it if the work I’m doing means something right. And that means that, as an employer, you need to change that as well.” When I asked him if this means that Amazon itself may also have to change its vaunted set of leadership principles (the ones new employee at Amazon basically has to memorize), he noted that “with scale and success comes broad responsibility” — the final of the 16 leadership principles. Amazon, he stressed, also has a whole division focused on Social Responsibility and Impact. Who can you even trust anymore? In that context, he also noted that one of his predictions for next year is about fighting misinformation and — within that context — supporting open source intelligence. “We have rapidly shifted from an era of prolonged news cycles that lasted weeks or months to a constant stream of updates that break at the speed of a click. Social media platforms have become a primary source for disseminating and consuming news, and it’s never been harder to distinguish between what’s true and false,” he writes in his prediction blog post. If technology brought us fake news, “then it’s also our responsibility as technologists to go the other way around to find solutions,” he told me. He believes that solutions like browser sidebars that display relevant context — and maybe academic research — about a given topic, could be helpful, for example. “Elon is really good in time to push the story that media can’t be trusted,” Vogels said. “And since there’s many competing voices, can you trust the Washington Post and The New York Times and LA Times? Can you, or not? I mean, in the past, these used to be the source of truth. There was no discussion. If you were published in the Frankfurter Allgemeine, everybody in Germany would read that and know that that’s the truth. But can we help with technology? Is there a general perception, at least during the US, recent US elections, that the general media can be trusted? At least one candidate is pushing that story very hard. Then we need to make sure that there is context around those stories that demonstrate which ones are telling the truth or not.” “If we look at X and sort of the community notes, I’m not really sure whether the community notes are terribly useful, but [they] should be. And the question is, can we automate these kind of things?” Meanwhile, the organizations doing open-source intelligence work, he said, are often not using the most advanced technology. He believes that locating where an image was taken, for example, should be automated by using image recognition. Similarly, he hopes that access to open data will help NGOs to improve their disaster preparedness by allowing them to build better maps in areas where commercial mapping isn’t financially viable, for example, or by building new real-time data sources for tracking wildfires. Fighting tech addiction Vogels also noted that one of the reasons technology has been such an accelerant for the spread of misinformation is because our devices and apps have become so addictive. “We have tremendous impact with our technology on the lives of people, not only in terms of whether we advocate for what’s the truth, but the amount of time we spend with technology,” he said. Applications today, he said, are essentially built to be sticky and addictive. “We as adults may be able to handle that,” he said (though I’ll interject here that I’m not sure if adults actually can). “You know, if your kid of four years old is sitting in the back of the car, and, you know, in the past, they will be singing or yammering: ‘Are we there? Are we there?’ But [what] parents now do is just give them an iPad. Kids at four or five years old know how to use YouTube, but it also means that they get on a cycle of continuous highs, continuous highs, continuous highs. So the expectation is that these kids, and we already see that, are more prone to other types of addiction later as well, because you need to continuously get this next high whether it’s drugs, food, drinking, sex, or whatever.” People, he believes, are realizing this now and starting to take some action — maybe that’s using a dumb phone or going offline for extended periods. He noted that new regulations in Australia, which seek to ban kids under 16 from using social media, “is a pretty brute force approach, but it does signal a problem,” even if forbidding something to teenagers will make it more appealing, of course. “After all, you know, in the Netherlands [where cannabis has long been tolerated], a lot [fewer] kids continue to smoke weed because it wasn’t cool.” It’s up to technologists to ensure that their applications aren’t addictive — maybe by making the interfaces simpler, for example. “I mean, probably for TechCrunch, if somebody reads one article, you wanted them to read more articles. After all, pageviews equals income. It’s a business. But you know, how addictive do you make your interfaces, right? And yes, of course, as a company, you have a responsibility to shareholders to do that, but I think these days, we also have a social responsibility to make sure that our society is healthy enough in ten, twenty years from now that you can continue to be in business.” The nuclear option This year’s set of predictions is a bit of “all over the place” (Vogels’ words, not mine), and his next one is about the use of nuclear energy. In Vogels’ view, the expansion of nuclear energy and the growth of renewable energy “will lay the groundwork for a future where our energy infrastructure is a catalyst for innovation, not a constraint.” “We know how to do small nuclear,” he told me — referring to the reactors used to power military submarines, for example. “We just never built them because they weren’t commercially interesting. Plus, society didn’t accept them as being [located] somewhere near them. If your submarine will go up in flame, fine, submarine, you chose for that. It’s a different story.” But we’ve now also reached a point where large businesses aren’t allowed to build new facilities near cities like Amsterdam, where Vogels lives, because the energy companies can’t deliver enough electricity to them anymore — not because they can’t generate enough. A few years ago, Vogels told me that he wasn’t ready to retire yet . I don’t get the sense that anything has changed for him. He’s clearly still enjoying his role — even if his predictions this year are a bit darker than usual.

In addition, Tencent Video has also introduced new features and improvements to enhance the overall user experience. This includes enhanced video quality, improved user interface, and a more personalized recommendation system. These upgrades are designed to make the viewing experience more enjoyable and engaging for users, regardless of their device-sharing settings.Boosting volunteer numbers key to addressing hunger in Virginia, Youngkin says“Cassoulet, that best of bean feasts, is everyday fare for a peasant but ambrosia for a gastronome.” ~ Julia Child When winter heads our way, bringing chilly temperatures and close, dark nights, my thoughts turn to Cassoulet, the iconic comfort food from southwestern France. It has it all – juicy beans, duck leg confit, sausages and sometimes pork or lamb, slowly simmered in well-seasoned broth, then baked in a wide-mouthed, glazed terra-cotta dish called a cassole . Like any truly traditional dish, there are multiple versions, all claiming to be the “authentic one.” Cassoulet originated in southwestern France. Toulouse claims it — and so does Castelnaudary and Carcassonne — and the recipes vary. Toulouse adherents eschew adding cubed pork. Castelnaudary purists add a bit of lamb, while Carcassonne’s adds partridge. In most restaurants, cassoulets are served in an individual cassole , bubbling with hot juices,and with a bit of duck leg peeking through the top. But at Hostellerie Etienne , a vast indoor- outdoor restaurant on the edge of a forest near Castelnaudary, the cassoulets come to the table in family-size cassoles , big enough to serve two, four, six or even 10 people, so you can share the dish with your dining companions. I don’t know if Etienne’s even has a single-serving bowl size. I didn’t see one, when I was there as the guest of a bean trader from Castelnaudary. According to him, Etiennne’s has the best cassoulet anywhere, and they use the Lauragais lingot beans known as the Castelnaudary bean. Copious doesn’t begin to describe the cassoulet scene there, with stacks of cassoles lined up in Etienne’s kitchen, next to caldrons of simmering beans, ready to be filled and popped into the vast ovens. Here in the Bay Area, we have our own go-to restaurants for cassoulets. Some, like the Left Bank Brasseries in San Jose, Menlo Park, Oakland and Larkspur, and Reve Bistro in Lafayette, only serve it during the winter months as a special. (Reve will be serving cassoulet Dec. 10-14, for example, and Jan. 7-11; reserve it when you reserve your table.) Others, such as Bistro Jeanty in Yountville and Le Central in San Francisco, always have it on the menu. Both Reve Bistro and Bistro Jeanty use cassoles made by potter Kathy Kernes at her Crockett Pottery in Crockett, and they are every bit as beautiful and as practical as those you’ll find in southwestern France. Kernes’ makes cassoles in six sizes ($38-$210), ranging from individual to “extra large plus,” which is very large indeed. (Browse the possibilities at www.crockettpottery.com.) Reve Bistro offers take-out cassoulets if you pre-order the week the dish is on the menu. Pick it up — in a takeout container, not a cassole! — then heat it at home. Just note that chef-owner Paul Magu-Lecugy only makes a limited number of portions. “It’s time consuming,” he says, noting for him, it is a two-day process. Le Central’s cassoulet is one of the more elaborate around, with lamb, pork shoulder and boudin blanc, as well as the all-important duck leg confit and slightly garlicky Toulouse sausage. Left Bank uses chef-owner Roland Passot’s recipe (see below) and keeps it simple, limiting the meats to duck leg confit and Toulouse sausages. (Don’t panic. If you’re making this at home, some specialty markets sell duck confit.) The beans are key to cassoulet. Once cooked, they should not be mushy, but hold their shape after the long cooking. In France, tradition calls for either Tarbais beans, a plump, white bean, or lingot beans — a strain of cannellini beans — in making cassoulet. As Passot suggests in his recipe below, you can substitute cannellini beans or Great Northern beans. Rancho Gordo produces a variety called cassoulet , a West Coast-grown bean from the Tarbais strain. Cassoulet isn’t difficult to make. It just requires time and patience. You can make it a couple of days ahead, refrigerate it and then slowly reheat it. That way, there’s nothing to do on the day of but sip a glass of wine while the beans and meats slowly heat to bubbling. Add a green salad and some crusty bread, and you’ll have the perfect winter meal. Or put your coat on and head to one of our local restaurants, where the cooking is done for you. All you need is a reservation. Serves 6 to 8 Beans: 4 cups dried lingot beans (white kidney, cannellini or Great Northern, will all work) 1 small carrot, peeled and chopped 1 small onion, diced (about 3⁄4 cup) 1 clove garlic, chopped 1 pound slab bacon or extra thick-cut bacon, cut into 1-inch cubes 2 sprigs of thyme 1 bay leaf Cassoulet: 1⁄4 cup duck fat (lard will do in a pinch) 2 pounds pork butt cut in 2-inch cubes 1 cup onions, diced small 4 cloves garlic, chopped 1⁄4 cup tomato paste 1 small can diced tomatoes 11⁄2-2 cups reserved bean water 6 Toulouse sausages 1 small garlic sausage 4 confit duck legs, purchased or homemade (see note below) 1 cup panko bread crumbs 1 teaspoon garlic, chopped 1 tablespoon parsley, chopped 1⁄4 teaspoon fresh thyme, chopped 1 tablespoon extra virgin olive oil Note: If you are making your own duck confit, start the night before by rubbing the duck legs with a “green salt” mixture — kosher salt, parsley, a couple of bay leaves and thyme ground together. The next day, rinse the duck legs well, pat dry and place in an oven-safe cooking vessel with enough duck fat to cover the legs. Roast in a 225-degree oven for 21⁄2 to 3 hrs. The night before, place the beans in a deep pot and add enough water to cover by 2 inches. Let beans soak overnight. The next day, rinse the beans well. Add the rinsed beans, carrots, onions, garlic, bacon, thyme and bay leaf to cold water and cook, over low heat, until the beans are tender. Strain the beans, saving the water, and set aside the beans. In a large braising pan, melt the duck fat over medium high heat. Once the pan is hot, brown the pork butt pieces without stirring. When beginning to brown, start stirring, making sure you scrape the bottom if it starts to caramelize. The pork doesn’t need much color, but it does need to cook in the duck fat for a while. Add lots of salt and pepper. This is not a shy dish. When the pork is nice and brown on all sides, add the 1 cup onions and garlic, and sauté until the onions are soft and cooked through. Add the tomato paste, diced tomatoes and reserved liquid from the beans. Stir, using a rubber spatula to clean the side of the pot. Preheat your oven to 250 degrees. Bring the heat under the braising pan up to high. Once at a rolling boil, turn down to low heat and add all the sausages. When they are cooked through, remove and set aside. Slice the garlic sausage in half and cut into 1-inch pieces. Return the whole and sliced sausages back to the pot along with the cooked beans. Continue to cook on low heat until the pork is cooked through. Taste for seasoning; add more salt and pepper if needed. Transfer the beans and pork to a heavy, wide mouth, earthenware, clay or cast iron baking dish that can hold 5 to 6 quarts. Bake at 250 degrees for about 11⁄2 hours, checking at least every 30 minutes. It may require a bit more time. If the dish is starting to look too dry, add a small amount of reserved bean broth or chicken stock. Add warmed duck legs to the cassoulet and make a breadcrumb topping by combining the panko, garlic, parsley, thyme and extra virgin olive oil. Return the dish to the oven and continue baking until the crumbs brown on the top. — Courtesy Roland Passot, Propriétaire, Chef Culinary Officer, Vine Hospitality

WALTHAM, Mass. , Dec. 19, 2024 /PRNewswire/ -- Veralto (NYSE: VLTO), a global leader in essential water and product quality solutions dedicated to Safeguarding the World's Most Vital ResourcesTM , announced today that its board of directors has approved a 22% increase to its quarterly cash dividend, and accordingly approved a quarterly cash dividend of $0.11 per share of its common stock, payable on January 31, 2025 to holders of record as of the close of business on December 31, 2024 . About Veralto With annual sales of $5 billion , Veralto is a global leader in essential technology solutions with a proven track record of solving some of the most complex challenges we face as a society. Our industry-leading companies with globally recognized brands are building on a long-established legacy of innovation and customer trust to create a safer, cleaner, more vibrant future. Headquartered in Waltham, Massachusetts , our global team of 16,000 associates is committed to making an enduring positive impact on our world and united by a powerful purpose: Safeguarding the World's Most Vital ResourcesTM . View original content to download multimedia: https://www.prnewswire.com/news-releases/veralto-announces-increase-in-quarterly-dividend-302336275.html SOURCE Veralto

"Marvel Duel" is a strategic card game that brings together iconic Marvel heroes and villains in a battle for supremacy. Players can build their custom decks, strategically deploy powerful abilities, and engage in intense one-on-one battles with other players in real-time. The game's easy-to-learn mechanics, stunning visuals, and deep strategic gameplay have resonated with fans of both Marvel and card games, leading to its rapid growth in player numbers.CME Group Tour Championship Par Scores4. Supporting key industries: Governments are expected to provide targeted support to industries that have been severely impacted by the pandemic, such as tourism, hospitality, and retail. By offering financial assistance, regulatory relief, and market access facilitation, governments can help these industries recover, create jobs, and contribute to overall economic growth.

One of the key factors that have contributed to the success of this visa-free initiative is the warm hospitality and friendliness of the South Korean people. From the moment Chinese visitors step foot in the country, they are greeted with smiles and welcoming gestures, making them feel right at home. This genuine hospitality leaves a lasting impression on Chinese travelers, often prompting them to return and recommend South Korea to their friends and family.The incident took place at a remote location, hidden from the public eye but not from the lenses of vigilant netizens. Images of individuals kneeling on the ground while being struck by batons raise serious concerns about the working conditions and treatment of employees in such establishments.Arsenal, Man City and Bayern advance to Women's Champions League quarterfinals

The Latest: Police search for man who killed UnitedHealthcare CEO, new photos of suspect released

The story of the "host" Zhang who sheltered a lost 13-year-old female master's student from Shanxi: Held banquets, did not restrict her

Pittsburgh Penguins forward Philip Tomasino will miss Saturday’s home game against the Toronto Maple Leafs at PPG Paints Arena due to an undisclosed injury. Coach Mike Sullivan revealed Tomasino’s status approximately two hours before the opening faceoff and labeled him as “day to day.” Tomasino did not record a shift beyond the 13:43 mark of the third period of a 4-2 road loss to the New York Rangers on Friday. He scored a goal in the third period of that contest. The Penguins acquired Tomasino in a trade with the Nashville Predators on Nov. 25. Since joining the Penguins, Tomasino has primarily been deployed on the second line as well as the second power-play unit and has scored four points (three goals, one assist) in five contests while averaging 14:59 of ice time. Notes: • Penguins goaltender Tristan Jarry is scheduled to start Saturday’s game according to Sullivan. In nine games this season, Jarry has a 4-3-1 record, a 3.88 goals against average and an .884 save percentage. Throughout his career, Jarry has faced the Maple Leafs in nine contests, posting a 5-3-0 record, a 2.86 goals against average, a .910 save percentage and one shutout. • With both teams traveling overnight following games on Friday, neither the Penguins nor the Maple Leafs staged a morning skate on Saturday. • Sullivan is slated to appear in his 700th game as the Penguins’ coach. • The Maple Leafs are scheduled to start goaltender Joseph Woll. In nine games this season, Woll has a 7-2-0 record, a 2.11 goals against average, a .922 save percentage and one shutout. Woll has faced the Penguins in only one game during his career. He made 32 of 35 saves in a 3-2 road loss, Nov. 25, 2023 .

Laptop or desktop: which is better?(PRNewsfoto/Aadi Bioscience) Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO ® and Associated Infrastructure to KAKEN Pharmaceutical for $100M ; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. ( HANGZHOU DAC), a global leader in ADC innovation. Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6). Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265 million , cumulative commercial milestone payments of up to $540 million and single-digit royalties of sales. To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $100 million , before deducting placement agent fees and other offering expenses. The Company is selling an aggregate of 21,592,000 shares of its common stock ("Common Stock") at a price of $2.40 per share, representing a premium of approximately 3.4% to the closing price on December 19, 2024 on Nasdaq, and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 20,076,500 shares of Common Stock at a purchase price of $2.3999 per Pre-Funded Warrant share. The syndicate was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners. The PIPE financing is expected to close in the first half of 2025, subject to stockholder vote and satisfaction of customary closing conditions. "I'm thrilled to announce our partnership with WuXi Biologics and HANGZHOU DAC to bring forward this thoughtfully selected ADC portfolio. We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier therapies to deliver improved outcomes for people living with cancer," said David Lennon , PhD, President and CEO of Aadi Bioscience. "The financing underscores the confidence our investors have in both the potential of this portfolio and the strength of Aadi's management team." About the ADC Portfolio Each of the three ADC assets utilizes HANGZHOU DAC's CPT113 ADC platform, which consists of a highly stable yet cleavable linker that delivers a Topoisomerase I (TOPO1) inhibitor payload. The CPT113 platform's linker stability and novel payload has the potential to be highly competitive among the next generation ADC platforms. To effectively leverage the CPT113 platform, Aadi selected tumor targets that are upregulated in high-potential cancer indications and where clinical efficacy has been demonstrated by first-generation ADCs. These assets were discovered through the collaborative efforts of WuXi Biologics and HANGZHOU DAC, utilizing the innovative antibody discovery platform provided by WuXi Biologics and advanced linker-payload technology provided by HANGZHOU DAC. "Leveraging our advanced antibody discovery service, we're glad to enable Aadi to accelerate the discovery of precision therapies targeting some of the most challenging cancers," said Dr. Chris Chen , CEO of WuXi Biologics. "This collaboration underscores our wide recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop next-generation modalities. We look forward to partnering with Aadi and HANGZHOU DAC to expeditiously move these assets forward into clinical development and benefit patients worldwide." " HANGZHOU DAC's CPT-ADC platform is designed to enable next wave ADC capabilities that surpass first-generation technologies, including two programs already in clinical development in China ," said Dr. Robert Y. Zhao , President and CEO of HANGZHOU DAC Biotechnology. "As a global leader in ADC innovation, we are excited to partner with Aadi and WuXi Biologics to deliver this promising portfolio to patients." Aadi to Sell FYARRO for $100 Million , Cumulative Capital Expected to Fund Operations into Late 2028 In a separate agreement, KAKEN Pharmaceutical Co., Ltd., an R&D driven pharmaceutical company in Japan , has entered into a stock purchase agreement under which KAKEN will acquire Aadi Subsidiary, Inc. and all of its assets, including FYARRO ® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) and associated infrastructure, including the majority of Aadi employees who support the FYARRO ® business. FYARRO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), with cumulative revenue of $25.2 million reported over the prior four quarters ended September 30, 2024 . Per the terms of the agreement, Kaken will pay Aadi $100 million in cash at closing, subject to certain adjustments. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Upon the closing of this transaction, KAKEN will also acquire the rights to the Aadi name and trademark. "We are enormously proud of the impact FYARRO has had for people with PEComa, and Kaken's capabilities, coupled with the proven track record of the Aadi team, ensures physicians and patients will continue to have access to this critical treatment," said Lennon. The net proceeds from the PIPE financing and the sale of FYARRO, together with the Company's existing cash, cash equivalents and marketable securities are expected to fund operations into late-2028, including anticipated clinical data readouts for the ADC portfolio. Baiteng Zhao Appointed to the Board of Directors, Brings Significant ADC Expertise Baiteng Zhao, PhD, joins Aadi's board of directors. Zhao co-founded ProfoundBio, a clinical stage next-gen ADC developer, in 2018 and served as the Chairman and CEO of the company until it was acquired by Genmab for $1.8 billion in May 2024 . Prior to ProfoundBio, Dr. Zhao worked at Seagen (now part of Pfizer) for more than eight years and was responsible for the modeling and simulation strategies for the development pipeline and supported preclinical and clinical development of ADC drug candidates. "We are delighted to welcome Baiteng to our Board. His deep expertise and successful track record in ADC development will be instrumental as we tenaciously move this exciting portfolio forward," said Caley Castelein , MD, Chair of the Board of Directors of Aadi Bioscience. "I am thrilled to join the Board at this pivotal moment for Aadi," said Baiteng Zhao, PhD, Board of Directors of Aadi Bioscience and co-founder of ProfoundBio. "PTK7, MUC16 and SEZ6 represent highly promising targets that are commonly overexpressed in cancers with significant unmet therapeutic needs. Coupled with an advanced linker-payload platform that has the potential to enable next-gen ADCs, I believe Aadi is uniquely positioned to make a meaningful impact on patient outcomes. I look forward to collaborating with the leadership team and fellow Board directors to advance these innovative programs and drive transformative progress for patients." Advisors Leerink Partners is serving as financial advisor to Aadi on the sale of FYARRO and the licensing of the ADC portfolio. Jefferies LLC is acting as exclusive placement agent for the PIPE financing. Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to Aadi. McDermott Will & Emery LLP is serving as legal counsel to Kaken. Cooley LLP is serving as legal counsel to Jefferies LLC. Nomura Securities Co., Ltd. is serving as financial advisor to KAKEN. Conference Call Information The Aadi management team is hosting a conference call and webcast tomorrow, Friday, December 20 th at 8:00 AM EST ( 5:00 AM PST ) to discuss these updates. Participants may access a live webcast of the call and the associated slide presentation on these data through the "Investors & News" page of the Aadi Bioscience website at aadibio.com . To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. Additional Information for Stockholders This communication relates to the proposed sale of FYARRO and the proposed PIPE financing and may be deemed to be solicitation material in respect of such transactions. In connection with these proposed transactions, Aadi will file a Proxy Statement with the SEC. This communication is not a substitute for the Proxy Statement or any other documents that Aadi may file with the SEC or send to Aadi stockholders in connection with the proposed transactions. Before making any voting decision, investors and securityholders are urged to read the Proxy Statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transactions as they become available because they will contain important information about the proposed transactions and related matters. Stockholders may obtain a copy of the Proxy Statement and other documents the Company files with the SEC (when they are available) through the website maintained by the SEC at www.sec.gov , as well as on the Investor and News section of Aadi's website at www.aadibio.com . Certain stockholders of Aadi holding approximately 36% of Aadi's outstanding shares, as of the date hereof, including members of its board of directors and related entities, have entered into voting and support agreements in favor of KAKEN Pharmaceutical and Aadi, pursuant to which such stockholders have agreed to vote in favor of the stock purchase transaction with KAKEN Pharmaceutical and the other transactions described above. Participants in the Solicitation Aadi and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Aadi in connection with the proposed transactions. Information about Aadi's directors and executive officers is set forth in Aadi's definitive proxy statement filed with the SEC on April 26, 2024 , and in subsequent filings made by Aadi with the SEC. Other information regarding the interests of such individuals, as well as information regarding Aadi's directors and executive officers and other persons who may be deemed participants in the proposed transactions, will be set forth in the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these documents as described in the preceding paragraph. No Offer or Solicitation This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor a solicitation of any vote or approval with respect to the proposed transactions or otherwise, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offer and sale of securities of Aadi described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the subscription agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file, following the closing of the PIPE financing, a registration statement with the SEC registering the resale of the shares of Common Stock and the shares of Common Stock underlying the Pre-Funded Warrants sold in the PIPE financing. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on LinkedIn. Forward-Looking Statements This press release contains certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the timing and completion of the proposed sale of FYARRO to Kaken Pharmaceuticals and the anticipated timing of the closing of the transaction; expectations regarding the timing, closing and completion of the PIPE financing; Aadi's expected cash position at the closing and cash runway of the company following the sale of FYARRO and PIPE financing; the future operations of Aadi; the development and potential benefits of any of Aadi's product candidates, including the preclinical ADC assets proposed to be licensed from WuXi; anticipated preclinical and clinical development activities and related timelines, including the expected timing for announcement of data and other preclinical and clinical results and potential submission of IND filings for one or more product candidates; and other statements that are not historical fact. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with (i) the risk that the conditions to the closing of the proposed sale of FYARRO or the PIPE financing are not satisfied, including the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Kaken and Aadi to consummate the proposed sale of FYARRO; (iii) risks related to Aadi's ability to manage its operating expenses and its expenses associated with the proposed transactions pending the closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions; (v) unexpected costs, charges or expenses resulting from the transactions; (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed sale of FYARRO or the proposed PIPE financing; (vii) the uncertainties associated with Aadi's product candidates, as well as risks associated with the preclinical and clinical development and regulatory approval of product candidates, including potential delays in the completion of preclinical studies and clinical trials; (viii) risks related to the inability of Aadi to obtain sufficient additional capital to continue to advance these product candidates; (ix) uncertainties in obtaining successful preclinical and clinical results for product candidates and unexpected costs that may result therefrom; (x) risks related to the failure to realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with the possible failure to realize certain anticipated benefits of the proposed sale of FYARRO or the proposed PIPE financing, including with respect to future financial and operating results. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including under the caption "Item 1A. Risk Factors," and in Aadi's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Aadi's reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at www.sec.gov . All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: IR@aadibio.com View original content to download multimedia: https://www.prnewswire.com/news-releases/aadi-bioscience-transforms-with-in-licensing-of-novel-adc-portfolio-100-million-sale-of-fyarro-and-100-million-pipe-financing-302336743.html SOURCE Aadi BioscienceWhere to Watch Alcorn State vs. Jackson State on TV or Streaming Live – Nov. 23

Gerry Dulac: Steelers defense failed to close out a win — again